|
|
|
|
||
PATENTS TO DATE PER SARAHThe patents we have are listed below as in the Annual Information Form Intellectual Property We devote significant resources to ensure protection of the ideas and inventions related to core areas of our business. Our intellectual property portfolio covers compositions, methods and treatments for the treatment of unmet medical needs related to major adverse cardiovascular events in patients with higher risk such as acute coronary syndrome, peripheral arterial disease, diabetes mellitus and chronic kidney disease. As of July 27, 2015, we own and/or have rights to numerous patent families, comprising ten issued US patents and a number of pending applications. This includes non-provisional US and provisional applications. The pending patent applications are largely interrelated and assert rights to substantially similar inventions in different jurisdictions. In fiscal 2012, Resverlogix was granted four patents, including a United States Patent covering composition of matter claims to RVX-208, and a United States Patent covering the manufacturing of RVX-208. In fiscal 2013, Resverlogix was granted seven patents including a United States Patent related to inflammatory diseases. In fiscal 2014, Resverlogix was granted eleven patents, including a patent in Europe containing composition of matter claims to RVX-208. In fiscal 2015, Resverlogix was granted eighteen patents including United States patents related to use claims for RVX-208 and manufacturing of RVX-208. Our intellectual property strategy is to build a strong patent portfolio around core technology that is important to development of leading edge medicines. Our strategies include being the first to identify, isolate, and patent therapeutic agents with commercial importance, to seek out and license intellectual property believed to be useful in connection with potential products, and to control public disclosures. We also believe that our know-how will provide a significant competitive advantage, and intend to continue to develop and protect our proprietary tools, methods and trade secrets. Our policy is to require employees, consultants, members of our boards and other 20 third parties in collaborative agreements to execute confidentiality agreements. Employee, consultant and contract research organization agreements specify that all inventions resulting from work performed utilizing our property, business strategies, and work completed during employment/services performed are our exclusive property to the extent permitted by law. From: JKJ193741 Sent: February 8, 2016 8:52 AM To: Sarah Zapotichny Subject: Crestor HAS RVX BEEN GRANTED A PATENT ON A 208 and Crestoe combo. Yet? Thanks Re: CRESTOR EXPIRES IN US IN MAY " No bites so far. In addition, Resverlogix has also filed for a fixed dose combination patent, with Rosuvastatin, that if granted will extend the patent life to 2033. " http://www.prnewswire.com/news-releases/resverlogix-update-250655411.htm |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
26090 | Re: PATENTS TO DATE PER SARAH | Fundamentals6 | 1 | 2/8/2016 6:28:02 PM |